ALDH1a2 Inhibitors

Product Overview

Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis

Development Status: Active Development

Target: Male

Mode: Non-hormonal

Delivery Type: Oral

Duration Type: Long-acting

Description: ALDH1A2 is an enzyme involved in testicular retinoic acid biosynthesis, that if blocked can arrest spermotogenesis. Small molecule inhibitors of ALDH1A2 are being developed as long-term oral, reversible male contraceptives, based on earlier work on bisdichloroacetyldiamines (BDADs).

Updated date: May 30, 2018

Vertical Tabs

Product Details

Active Pharmaceutical Ingredient (API): ALDH1A2 inhibitors

Potential Multi-Purpose Technology (MPT): No

Regimen: daily

Duration: Months to years

Partner: University of Washington, University of Minnesota

Status

Project Phase: Early Development

Project Stage: Pre-clinical

Status Details:
Currently conducting preclinical, in vitro, and early-phase animal testing.

Programmatic Considerations

Considerations:
While BDADs resulted in unpleasant disulfiram reactions, ALDH1A2 inhibitors would be testes-specific and thus avoid the disulfiram reactions.

Additional Information

Additional Information:
Paik J, et al. (2014) Inhibition of Retinoic Acid Biosynthesis by the Bisdichloroacetyldiamine WIN 18,446 Markedly Suppresses Spermatogenesis and Alters Retinoid Metabolism in Mice. The Journal of Biological Chemistry. 289(21);15104-15117

Footnotes:
See entry on Bisdichloroacetyldiamines (BDADs).

Download Product Report

Alternative Name: Inhibitors of Testicular Retinoic Acid Biosynthesis

Development Status: Active Development

Target: Male

Mode: Non-hormonal

Delivery Type: Oral

Duration Type: Long-acting

Description: ALDH1A2 is an enzyme involved in testicular retinoic acid biosynthesis, that if blocked can arrest spermotogenesis. Small molecule inhibitors of ALDH1A2 are being developed as long-term oral, reversible male contraceptives, based on earlier work on bisdichloroacetyldiamines (BDADs).

Updated date: May 30, 2018

Vertical Tabs

Active Pharmaceutical Ingredient (API): ALDH1A2 inhibitors

Potential Multi-Purpose Technology (MPT): No

Regimen: daily

Duration: Months to years

Partner: University of Washington, University of Minnesota

Project Phase: Early Development

Project Stage: Pre-clinical

Status Details: Currently conducting preclinical, in vitro, and early-phase animal testing.

Considerations: While BDADs resulted in unpleasant disulfiram reactions, ALDH1A2 inhibitors would be testes-specific and thus avoid the disulfiram reactions.

Additional Information: Paik J, et al. (2014) Inhibition of Retinoic Acid Biosynthesis by the Bisdichloroacetyldiamine WIN 18,446 Markedly Suppresses Spermatogenesis and Alters Retinoid Metabolism in Mice. The Journal of Biological Chemistry. 289(21);15104-15117

Footnotes: See entry on Bisdichloroacetyldiamines (BDADs).

Status Details:
Currently conducting preclinical, in vitro, and early-phase animal testing.

Considerations:
While BDADs resulted in unpleasant disulfiram reactions, ALDH1A2 inhibitors would be testes-specific and thus avoid the disulfiram reactions.

Additional Information:
Paik J, et al. (2014) Inhibition of Retinoic Acid Biosynthesis by the Bisdichloroacetyldiamine WIN 18,446 Markedly Suppresses Spermatogenesis and Alters Retinoid Metabolism in Mice. The Journal of Biological Chemistry. 289(21);15104-15117

Footnotes:
See entry on Bisdichloroacetyldiamines (BDADs).